ReviewInternational journal of physiology, pathophysiology and pharmacology2019
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.
Review in International journal of physiology, pathophysiology and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Pooled it
- Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis.Molecular neurobiology · 2021Pooled it
- The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.British journal of clinical pharmacology · 2020Pooled it
- Review
- Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania.Journal of clinical medicine · 2025Article
- Fingolimod-associated cryptococcal meningitis in a patient with Multiple Sclerosis: A case report and literature review.IDCases · 2025Article
- Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative.Journal of managed care & specialty pharmacy · 2024Article
- Effect of Silybum Marianum on Reduction of Chemotherapy-Induced Peripheral Neurotoxicity with Cisplatin.Advanced biomedical research · 2024Article
- Histoplasmosis in a fingolimod-treated patient: case report and scoping review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Article
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
- Decision Curve Analysis for Personalized Treatment Choice between Multiple Options.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple blind randomized clinical trial.Frontiers in nutrition · 2023Article
- Evaluation of the Relative Frequency of Epstein-Barr Virus Infection in Patients with Recurrent Breast Cancer Compared with Patients with Nonrecurrent Breast Cancer.Advanced biomedical research · 2023Article
- Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.International journal of molecular sciences · 2022Article
- Platelet-rich plasma therapy or arthroscopic surgery on repair of anterior cruciate ligament rupture.European journal of translational myology · 2022Article
- DYT-Biomolecules · 2022Article
- Review
- Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women.International journal of physiology, pathophysiology and pharmacology · 2022Article
- Contrast-enhanced weighted-T1 and FLAIR sequences in MRI of meningeal lesions.American journal of nuclear medicine and molecular imaging · 2022Article
- Predictive value of number and volume of demyelinating plaques in treatment response in patients with multiple sclerosis treated with INF-B.American journal of neurodegenerative disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is chronic, inflammatory, a neurologic disorder of the central nervous system (CNS). Although the exact mechanisms of MS have not been yet discovered some drugs are found helpful for its treatment. These drugs which are divided into the first line, second line and third-line therapies, have demonstrated to be helpful for MS patients based on immune basic of the disease. Previous studies have been indicated that deterioration of MS condition is associated with a stronger immune system. Most of these therapies impact on the immune system and immune cells including shifting immune cell populations toward a Th2 dominant population or suppression of the immune system so that auto-reactive immune cells cannot attack myelin sheath of neurons. Beside many beneficial effects of these drugs, some adverse effects (AE) have been reported in many experiments and clinical trials among patients suffering from MS. In this review, we conclude some AEs of beta interferon, mitoxantrone, natalizumab and fingolimod, reported in different papers and we continue the rest of the drugs in second part of our review article.
Indexed as
Identifiers
31523357PMC6737429W2980706456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.